Improving Preclinical Study Accuracy Using PDX with Next-Gen Multiomic Datasets

Presented by

Stefano Cairo, PhD, Senior Global Scientific Director, Champions Oncology

About this talk

With an estimated 90% of oncology drugs failing clinical trials, there is a critical need for a more robust approach to preclinical and translational studies. Recent advances in high-throughput proteomics and multiomic analysis are revolutionizing our understanding of tumour biology. In this webinar we’ll discuss how Champions’ multiomics datasets, including proteomics and phospho-proteomics, and proprietary algorithms are used to improve model selection for ex vivo and in vivo studies and to reveal mechanisms of drug sensitivity and resistance. Webinar topics will include: - How to incorporate highly translational cancer models such as PDX, primary models and organoids into an effective preclinical research plan - Beyond RNASeq: systematic analysis of PDX proteome reveals indication-specific lack of correlation with RNA expression - Improving the selection of preclinical models with predictive kinase activity and pathway activation scoring - Using Champions’ Pharmaco-Pheno-MultiOmic (PPMOTM) analysis tools to discover new biomarkers of drug resistance/sensitivity: primary AML (Cytarabine) and Ovarian PDX (Olaparib) case study examples About the Presenter: Molecular biologist by training with PhD in human genetics, Stefano has a strong background in Translational Research in Oncology, with a specific focus on solid tumor cancer. Prior to joining Champions Oncology, Stefano supervised XenTech's PDX platform development in collaboration with several clinical centers. Stefano led several collaborative research projects which led to the identification and validation of new therapeutic targets, cancer pathways and gene signatures used to stratify patient population.
Related topics:

More from this channel

Upcoming talks (4)
On-demand talks (61)
Subscribers (3396)
Champions Oncology delivers innovative solutions to oncology drug development, accelerating the journey from the research bench to the clinic – decreasing timelines, lowering costs, and ultimately saving patient lives. Learn more about Champions Oncology's capabilities, our service platforms and educational topics affecting our industry on our Webinar Channel.